PMID- 23764990
OWN - NLM
STAT- MEDLINE
DCOM- 20140206
LR  - 20211021
IS  - 1476-5454 (Electronic)
IS  - 0950-222X (Print)
IS  - 0950-222X (Linking)
VI  - 27
IP  - 9
DP  - 2013 Sep
TI  - Microperimetric sensitivity in patients on hydroxychloroquine (Plaquenil) 
      therapy.
PG  - 1044-52
LID - 10.1038/eye.2013.112 [doi]
AB  - PURPOSE: The purpose of this study was to measure macular sensitivity using 
      microperimetry in patients on Plaquenil therapy without evidence of retinopathy 
      as assessed by recommended screening standards. METHODS: Sixteen patients from a 
      clinical practice treated with 200 or 400 mg/day of Plaquenil for more than 5 
      years, without visual complaints (visual acuity 20/25 or better), and without a 
      history of diabetes or macular disease were included. Participants underwent a 
      complete ophthalmic examination with spectral-domain optical coherence tomography 
      (SD-OCT), 10-2 Humphrey visual field (HVF), fundus autofluoresecene (FAF), 
      multifocal electroretinography (mfERG), and microperimetry that covered the 
      central 12 degrees  of the visual field. Ten age-similar, visually normal subjects served 
      as controls. RESULTS: The average age of the study cohort was of 54.5 years, with 
      an average daily Plaquenil dose of 4.00 mg/kg/day (range, 1.77-6.67 mg/kg/day) 
      and an average cumulative dose of 1485 g (range, 256-3650 g). All patients had 
      normal ocular exams, and no evidence of retinopathy based on 10-2 HVF, FAF, 
      mfERG, and SD-OCT. The mean retinal sensitivity by microperimetry was 15.0 dB 
      (OD) and 14.6 dB (OS). The overall mean microperimetry sensitivity of the 
      patients (14.7+/-1.9 dB) was significantly lower (P<0.001) than that of the 
      controls (16.5+/-2.1 dB). CONCLUSIONS: Patients on Plaquenil without clinical 
      evidence of retinal toxicity can have reduced retinal sensitivity, as assessed by 
      microperimetry. The mean sensitivity difference between the patients and controls 
      suggests that microperimetry can provide important information regarding visual 
      function in patients on Plaquenil therapy.
FAU - Jivrajka, R V
AU  - Jivrajka RV
AD  - Department of Ophthalmology and Visual Sciences, University of Illinois Chicago, 
      Chicago, IL, USA.
FAU - Genead, M A
AU  - Genead MA
FAU - McAnany, J J
AU  - McAnany JJ
FAU - Chow, C C
AU  - Chow CC
FAU - Mieler, W F
AU  - Mieler WF
LA  - eng
GR  - P30 EY001792/EY/NEI NIH HHS/United States
GR  - R00 EY019510/EY/NEI NIH HHS/United States
GR  - EY01792/EY/NEI NIH HHS/United States
GR  - R00EY019510/EY/NEI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
DEP - 20130614
PL  - England
TA  - Eye (Lond)
JT  - Eye (London, England)
JID - 8703986
RN  - 0 (Antirheumatic Agents)
RN  - 0 (Enzyme Inhibitors)
RN  - 4QWG6N8QKH (Hydroxychloroquine)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Analysis of Variance
MH  - Antirheumatic Agents/administration & dosage/*adverse effects
MH  - Cohort Studies
MH  - Connective Tissue Diseases/drug therapy
MH  - Electroretinography
MH  - Enzyme Inhibitors/administration & dosage/*adverse effects
MH  - Female
MH  - Fluorescein Angiography
MH  - Humans
MH  - Hydroxychloroquine/administration & dosage/*adverse effects
MH  - Male
MH  - Middle Aged
MH  - Retina/*drug effects
MH  - Retinal Diseases/*chemically induced/physiopathology
MH  - Tomography, Optical Coherence
MH  - Visual Fields/*physiology
PMC - PMC3772354
EDAT- 2013/06/15 06:00
MHDA- 2014/02/07 06:00
PMCR- 2014/09/01
CRDT- 2013/06/15 06:00
PHST- 2013/03/11 00:00 [received]
PHST- 2013/04/23 00:00 [accepted]
PHST- 2013/06/15 06:00 [entrez]
PHST- 2013/06/15 06:00 [pubmed]
PHST- 2014/02/07 06:00 [medline]
PHST- 2014/09/01 00:00 [pmc-release]
AID - eye2013112 [pii]
AID - 10.1038/eye.2013.112 [doi]
PST - ppublish
SO  - Eye (Lond). 2013 Sep;27(9):1044-52. doi: 10.1038/eye.2013.112. Epub 2013 Jun 14.